No abstract

Significant clinical benefits were observed for patients who used professional CGM. Economic benefits were observed for patients who utilized professional CGM more than once within a 1-year period or who used it during a change of diabetes therapy. This suggests that professional CGM may help decrease rising trends in healthcare costs for people with type 2 diabetes, while also improving clinical outcomes.

Insulin-treated patients experience hypoglycemic events, which are associated with substantial direct and indirect medical costs. The cost savings of reducing hypoglycemic events need to be weighed against the costs of using diabetes device interventions.

A245 objectives. Adult patients with type 2 diabetes mellitus (T2DM) newly initiating treatment between January 1, 2010, and December 31, 2011, with either saxagliptin or sitagliptin were identified. A 1:1 propensity-matched sample of saxagliptin and sitagliptin patients was created to reduce any potential confounding. Propensity scores were generated based on demographic characteristics, comorbidities, disease severity and treatment patterns before the index date. Patients were required to have ≥ 6 months of continuous eligibility before (baseline period) and after (followup period) treatment initiation. All outcomes were assessed based on an intent-totreat analysis in the 6-month follow-up period. Both overall and diabetes-specific charges were computed; breakdowns of medical and overall (medical plus pharmacy) charges were compared. Appropriate univariate statistical tests were applied to the propensity-matched sample to examine differences in resource utilization outcomes. Results: A total of 8,438 and 23,155 patients initiated treatment with saxagliptin and sitagliptin, respectively. After matching, each cohort consisted of 7,700 patients. Compared with sitagliptin, during the follow-up period, saxagliptin was associated with significantly lower (all p values ≤ 0.